US allows first drug from DNA-altered animalsFebruary 7th, 2009 - 11:52 am ICT by IANS
Washington, Feb 7 (Xinhua) The US Food and Drug Administration (FDA) has approved the first drug made using genetically engineered animals, clearing the way for a new class of medical therapies. The drug, GTC Biotherapeutics Inc’s anti-clotting therapy Atryn, is an intravenous therapy made using a human protein gathered from female goats that have been scientifically altered to produce extra antithrombin, a protein that acts as a natural blood thinner.
Atryn aims to prevent excessive blood clots in patients with a disorder known as hereditary antithrombin deficiency. The Framingham, Massachusetts-based company estimates the disorder affects anywhere from 60,000 to 600,000 people in the US.
People with hereditary antithrombin deficiency are at increased risk for venous thromboembolic events, including pulmonary embolism and deep vein thrombosis, which can be life-threatening, particularly in high risk situations.
The FDA approved Atryn to prevent blood clots from surgery or childbirth in patients with the condition, but not wider use to treat the disorder itself, the company said in a statement.
“The approval of Atryn marks a significant milestone in the development of this innovative recombinant technology and delivers a new therapeutic option to benefit hereditary antithrombin deficient patients who are undergoing surgery or childbirth procedures,” said Geoffrey F. Cox, GTC’s chairman and chief executive officer.
The drug’s approval Friday may be the first step toward new kinds of medications made not from chemicals, but from living organisms altered by scientists.
- Dangerous, deep blood clots should be treated aggressively: Docs - Mar 22, 2011
- Risk of blood clot after surgery higher than previously thought - Dec 04, 2009
- Inflammatory bowel disease flare-ups raise blood clot risk - Feb 11, 2010
- Obese women face higher risk of vein clots - Apr 20, 2012
- Assessment tool predicts blood clot risk following plastic surgery - Nov 19, 2010
- Statins may help prevent blood clots in heart patients - Nov 04, 2009
- Scientists develop painless method to prevent fatal blood clots - Aug 12, 2009
- Gene mutation ups blood-clot risk in women taking breast cancer treatment - Jun 17, 2010
- Low iron levels tied to blood clot risk - Dec 15, 2011
- Soon, drug to prevent blood clots without increasing bleeding risk - Aug 12, 2009
- Statins cut risk of clot-related diseases - May 17, 2010
- New drugs show promise in treating dangerous blood clots - Jan 12, 2011
- Indian scientist links hereditary factors to abdominal venous thrombosis - Oct 11, 2008
- Sitting too long at work can be fatal - Nov 07, 2010
- Controller clears clot-buster drug for human trial - Aug 17, 2012
Tags: biotherapeutics, chief executive officer, childbirth procedures, deep vein thrombosis, deficient patients, female goats, food and drug administration, food and drug administration fda, framingham massachusetts, gtc biotherapeutics inc, human protein, intravenous therapy, living organisms, medical therapies, pulmonary embolism, recombinant technology, risk situations, therapeutic option, thromboembolic events, us food and drug administration